Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer study, denting enthusiasm for the programme just as there were signs that it was getting back on track after a series of disappointing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback